<DOC>
	<DOCNO>NCT02614131</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability study drug know LY2599666 different group people - healthy , mild cognitive impairment due Alzheimer 's Disease ( AD ) , mild-to-moderate AD . The study measure much LY2599666 get bloodstream long take body get rid . It also evaluate LY2599666 affect body . The study three part . Part A last 2 month . Parts B C last 23 week . Participants may enroll one part .</brief_summary>
	<brief_title>A Study LY2599666 Healthy Participants Participants With Mild Cognitive Impairment Alzheimer 's Disease ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Healthy Participants Part A : Overtly healthy male female determine medical history physical examination Have body mass index ( BMI ) 18.0 32.0 kilogram per meter square ( kg/mÂ² ) , inclusive Participants With Mild Cognitive Impairment Alzheimer 's Disease ( AD ) [ Part B C ] : Participants least 50 year old screening Present Mild Cognitive Impairment ( MCI ) due Alzheimer 's Disease ( AD ) mildtomoderate AD Have caregiver/study informant provide separate write informed consent participate Have adequate vision hear neuropsychological test opinion investigator Positive florbetapir scan All Participants Are currently enrol clinical trial involve investigational product offlabel use drug device concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2599666 , solanezumab , related compound component formulation , history significant atopy Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have abnormal blood pressure determine investigator Have significant allergy humanize monoclonal antibody , diphenhydramine , epinephrine , methylprednisone Require treatment monoclonal antibody Participants With Mild Cognitive Impairment Alzheimer 's Disease ( AD ) [ Part B C ] Have medical surgical condition lumbar puncture or/catheter insertion contraindicate Have contraindication magnetic resonance imaging ( MRI ) study , include claustrophobia , presence metal ( ferromagnetic ) implant , cardiac pacemaker compatible MRI Participants With Mild Cognitive Impairment Alzheimer 's Disease ( AD ) [ Part C ] Have lymphoma , leukemia , malignancy within past 5 year except basal cell squamous epithelial carcinoma skin resect evidence metastatic disease 3 year , cervical carcinoma situ , situ prostate cancer normal prostatespecific antigen post treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>